Regulatory Compliance

JOHANNESBURG – October 07, 2026 -- Roche Diagnostics has delivered two molecular testing instruments to the Institut National de Santé Publique (INSP) to expand Ebola testing capacity in the Democratic Republic of Congo, as confirmed cases from the Bundibugyo virus outbreak reached 8,067 with 3,901 deaths as of September 28, 2026.

Case fatality rate hits 48.4% across 60 health zones

UN Health Authority data cited by Roche puts the outbreak's case fatality rate at 48.4% across six provinces, with the World Health Organization classifying the risk level in the DRC as very high and maintaining the event as a public health emergency of international concern.

Nanjing, China – October 06, 2026 -- Scage Future (Nasdaq: SCAG) will change its American Depositary Share ratio from one ADS per one ordinary share to one ADS per fifteen ordinary shares, effective on or about October 30, 2026.

Reverse ADS split consolidates holdings fifteen-to-one

The ratio change will function as a one-for-fifteen reverse ADS split for existing holders. On the effective date, Citibank, N.A., the depositary bank, will automatically cancel existing ADSs and issue one new ADS for every fifteen previously held, with no action required from shareholders.

Fractional entitlements will be sold for cash

No fractional new ADSs will be issued. The depositary bank will aggregate and sell fractional entitlements, distributing net cash proceeds, after fees, taxes and expenses, to the affected ADS holders.

London – – October 06, 2026 -- Prohibition Partners has appointed Heidi Whitman as Managing Director of PPX, a new advisory and media pillar combining the firm's decade-old cannabis market infrastructure with her independent network of regulators, financiers and formulators across the UK, EU and Latin America.

Prohibition Partners merges a decade of client relationships with Whitman's independent advisory book

Prohibition Partners has worked with some clients since 2017, building intelligence, media and events infrastructure including Cannabis Europa, Cannabis Health, Mind Forward and Business of Cannabis. Whitman's own clientele, built across three independent ventures, a company exit and years of advisory work, now gains access to that full network under the PPX structure.

Lowell – October 06, 2026 -- Draper has broken ground on a 111,000-square-foot microelectronics facility in Lowell, Massachusetts, designed to onshore advanced chip packaging capacity that is currently 97% dependent on foreign production.

Draper's IMPACT Center targets a critical gap in U.S. chip packaging capacity

Colleen Anderson, Electronic Systems program director at Draper, said only 3 percent of chip packaging is performed in the United States today, leaving a domestic void the new Integrated Microelectronics Production & Advanced Chip Technology (IMPACT) Center intends to fill. The facility will house design, production, and packaging operations covering microelectronics through advanced precision navigation and timing systems, supporting high-mix, low-volume manufacturing for Draper's customer base.

Boston – October 06, 2026 -- RaySecur has partnered with DTS Industries, a Jackson County, Kentucky manufacturer, to produce critical mechanical components and calibration standards for its MailSecur concealed-threat detection systems on U.S. soil.

RaySecur shifts supply chain to domestic manufacturer in Appalachian Kentucky

The deal brings precision metal fabrication and system calibration work for MailSecur, a desktop T-ray screening system, into DTS Industries' Jackson County facility. DTS specializes in precision forming, custom machining, laser cutting, assembly and finishing, and holds ISO 9001 certification.

Washington, D.C. – October 06, 2026 -- CNBC's Becky Quick will moderate a rare disease leadership dialogue featuring the CEOs of BioMarin, Jazz Pharmaceuticals and Otsuka North America Pharmaceutical alongside NORD CEO Pam Gavin, the National Organization for Rare Disorders announced.

Panel convenes three biopharma chiefs at NORD's Breakthrough Summit on October 26

The session, titled "Next Decade of Rare Disease: A CEO Leadership Dialogue," takes place at 11 a.m. ET on Monday, October 26, in Washington, D.C., during the three-day NORD Rare Diseases & Orphan Products Breakthrough Summit running October 25–27. Participants include Alexander Hardy, President and CEO of BioMarin; Renee Gala, President and CEO of Jazz Pharmaceuticals; Tarek Rabah, President and CEO of Otsuka North America Pharmaceutical; and NORD CEO Pam Gavin.

Houston – October 06, 2026 -- CATCH Greater Houston has been named a Phase 1 winner in two of the ten awarded tracks of the Health at Home Challenge, a national competition run by the Administration for Community Living (ACL) within the U.S. Department of Health and Human Services.

CATCH secures dual recognition in federal care coordination competition

The nonprofit won as a community care hub within a national consortium led by the Oregon Wellness Network, spanning eight hubs across eight states, and separately as the designated lead of the Texas Hub Network, a statewide consortium formed with the Texas Health and Human Services Commission.

Lakeville, Mass. – October 06, 2026 -- Boston Green Company has named Dmitro Popovich as Director of Business Development for Terminal, Marine & Industrial Services, tasking him with expanding client partnerships across the Northeast's terminal and industrial operators.

Popovich brings 18 years of bulk liquid and dry bulk terminal experience to the role

Popovich's background spans petroleum and third-party cargo handling, safety and environmental compliance, capital planning, and maintenance coordination. He most recently served as Director of Operations at Sprague Operating Resources LLC, where he oversaw bulk liquid and dry bulk operations across five terminals in New Hampshire and Maine.

Grants, New Mexico – October 06, 2026 -- The Cibola County Board of Commissioners has passed a resolution recognizing the strategic importance of the Grants Mineral Belt and In-Situ Recovery (ISR) technology for uranium extraction, the Clean Energy Association of New Mexico (CLEAN) announced.

Cibola County formally endorses ISR as a path for uranium development

The county resolution acknowledges ISR's potential to extract naturally occurring uranium without generating tailings or requiring underground workings, according to CLEAN. CLEAN President Janet Lee-Sheriff said the vote reflects research by county officials and staff aimed at making an informed decision based on sound information.

Burlingame, Calif. – October 06, 2026 -- Enliven Therapeutics, Inc. (Nasdaq: ELVN) has reached alignment with the U.S. Food and Drug Administration on the final design of ENABLE-2, a pivotal Phase 3 trial testing relcobatinib against standard second-generation therapies in previously treated chronic myeloid leukemia (CML). The company remains on track to initiate the trial before year-end 2026.

FDA clears path for 450-patient head-to-head comparison

ENABLE-2 is designed to enroll approximately 450 adults with CML who have already received one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib at 80 mg once daily or an investigator-selected second-generation TKI -- dasatinib, nilotinib, or bosutinib. The primary endpoint is major molecular response (MMR) at Week 24, with MMR at Week 96 as a key secondary measure.